Source comparison
CJC-1295 No DAC vs Sermorelin: Research Protocol Comparison
Plasma Half-Life ~30 minutes 8–10 minutes CJC-1295 no DAC's extended half-life reduces dosing frequency and handling stress in long-term studies; Sermorelin's rapid clearance suits acute-response and crossover designs. Typical Dosing Range 100–200 mcg per inje
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- ~30 minutes
- 8–10 minutes
- CJC-1295 no DAC's extended half-life reduces dosing frequency and handling stress in long-term studies; Sermorelin's rapid clearance suits acute-response and crossover designs.
- Typical Dosing Range
- 100–200 mcg per injection
- 200–500 mcg per injection
- Sermorelin requires 2–3× the dose to achieve comparable GH AUC due to faster clearance. Factor this into per-subject cost calculations.
- Injection Frequency
- Once or twice daily
- Twice to three times daily
- CJC-1295 no DAC offers logistical advantage in large-cohort or multi-week studies where minimizing interventions matters.
- GH Release Pattern
- Sustained pulse over 30–60 minutes
- Sharp spike, returns to baseline within 60 minutes
- CJC-1295 no DAC mimics prolonged physiological GHRH stimulation; Sermorelin replicates natural pulsatile bursts with clean washout.
- Receptor Desensitization Risk
- Low with standard dosing
- Minimal due to rapid clearance
- Sermorelin's brief receptor engagement theoretically reduces downregulation risk, but no clinical evidence shows meaningful difference at research-grade doses.
- Storage Post-Reconstitution
- 2–8°C, use within 28 days
- Both compounds degrade identically once reconstituted. Refrigeration and 28-day use window apply equally.